Amag Pharma has?struck?a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its emerging hematology business.....
Gilead and Novartis are working to ramp up launches of their slow-starting CAR-T drugs, and both companies are hoping longer-term follow-up data will help do the trick.